$IBRX -Weekly Forensic Report Feb 15-20 2026: The Global Commercial Pivot- Report 1 February 21 2026 1. Regulatory Breakthroughs & Global Authorization EU Market Entry: On February 18, the European Commission granted Conditional Marketing Authorizationfor ANKTIVA + BCG for

$IBRX- $IBRX Next Week- The Institutional Validation Phase 1. The Scientific Catalyst: ASCO GU 2026 (San Francisco) The "Organ Preservation" Moat: Presentations on QUILT-3.032 Cohort B (Feb 26-28) will highlight a 96% disease-specific survival and 82% cystectomy avoidance at 36

$IBRX- Earnings Preview (March 2): The Institutional Inflection Point. Part 3 of our post on Feb 21 2026. ImmunityBio is set to report Q4/FY25 results on Monday March 2nd. This isn't just a binary event; it is the formal validation of a global commercial scale-up. Here is the

$IBRX- $IBRX Analysis: Deconstructing the ASCO GU "Survival Moat" - Feb 23, 5 Pm ET. Tomorrow While the market focuses on the March 2nd earnings call, the primary clinical catalyst for ImmunityBio ($IBRX) arrives tomorrow. The ASCO GU 2026 abstracts are scheduled for release on

Update on $IBRX Short Dynamics – Feb 23 Session: Despite hitting an intraday high of $11.00, $IBRX short sellers remain heavily entrenched. Live SI % of Float: 40.06% Utilization: Inventory is critical; shares available to borrow dropped from 750k pre-market to just 40k by

$IBRX- IBRX UPDATE: THE "BIOSHIELD" IS OFFICIAL The ASCO GU 2026 abstracts officially dropped at 5:00 PM ET today. For those seeing "0 results" on the search bar: This is a standard site indexing lag. The data is public and the embargo is LIFTED. The Clinical "Audit" (36-Month

$IBRX- IBRX OPTIONS DEEP DIVE: THE BULLS ARE CHARGING The $IBRX options flow today was nothing short of a "Bullish Sweep." While the stock tested $11.00, the options market was pricing in even higher levels for March. Data driven analysis based on the screenshots attached. 1-

$IBRX- IBRX SHORT SQUEEZE ALERT: THE PRESSURE IS MOUNTING. Data driven analysis only based on the screenshots attached. The "Short Thesis" just hit a clinical and financial brick wall. Today’s surge to $9.83 (+12.99%) has short sellers trapped in a massive "coiled spring" setup.

$IBRX- $IBRX: The "Smart Money" Flow (Institutional Data Breakdown) While retail focuses on daily price action, the world's largest asset managers significantly increased their conviction in ImmunityBio during the most recent reporting period. Q4 13F Filing Data Summary: 1.

$IBRX: The Roadmap is Playing Out Exactly as Planned. As we published here on Sunday, we are executing the Weekly strategy. Monday is in the books; Tuesday is the next major "Credentialing" event. 1- MONDAY: DATA AUDIT (COMPLETED) ASCO GU abstracts released (5 PM ET).

$IBRX- Holding and closing above $11 today will be key.

$IBRX- The Short Squeeze update Feb 24th 2026 If you’re looking at the charts and wondering why the price is jumping, here is the "simple" version of the data from today's Ortex and IBKR reports. Think of $IBRX as a crowded theater with 134 million people (the

$IBRX- The video of Dr. Patrick Soon-Shiong is a "thesis defense" for the Lymphocyte-Stimulating Agent (LSA) class. Here is the highly detailed, data-backed analysis. Most people think of $IBRX as a "bladder cancer stock." The reality? We are witnessing the birth of a new

$IBRX- $IBRX Options Intelligence Report While the headlines focus on the 700% revenue growth, the Options Flow is revealing the real story: institutional "Whales" are positioning for a massive move beyond $15.00. The Data-Driven Breakdown: 1- Extreme Bullish Sentiment (0.17

$IBRX Final Post tonight "Smart Money" Audit If you only watched the 17% jump today, you missed the real move. The Dark Pool and Institutional Flow data from Feb 24 suggest a massive supply absorption is underway. The "Institutional" Deep Dive: 1-The Dark Pool Absorption:

$IBRX- Headline: $IBRX: ZOOM OUT. THE MATH HAS NOT CHANGED. To everyone panicking at the $10.50 retest: You are watching a masterclass in "Shakeout Dynamics." The Reality Check: Shorts are Trapped: Today’s Ortex data shows 9.68M NEW shares borrowed. They aren't leaving; they

$IBRX- Data driven,Forensic Post-Mortem of the Feb 25 Devaluation and Path forward. Let's see if this analysis stands. Today was a humbling day and we did not see this coming.

$IBRX- Today belonged to the shorts we’ll give them that. But we’re still here. Still standing. Still fighting. Today’s -17.4% drop was painful for longs, but for the "Squeeze Thesis," the math just got a lot more explosive. While retail panics, here is what the actual tape is

$IBRX- $IBRX Options & Short Interest: The "Smart Money" vs. "The Raid" While the price action was brutal today, the data behind the scenes shows a massive divergence. Retail panicked, but "Whales" and Shorts just upped the ante. 1. Massive Institutional Call Buying (The Whale